Literature DB >> 8635635

Synchronous primary carcinomas of the endometrium and ovary.

B C Sheu1, H H Lin, C K Chen, K H Chao, C T Shun, S C Huang.   

Abstract

OBJECTIVES: Synchronous carcinomas of the endometrium and ovary may indicate either independently developing neoplasms or metastatic disease. The clinical implications and prognosis of these two categories are quite different. The objectives of this study were to identify and evaluate the empirical criteria and significant therapeutic implications.
METHOD: The National Taiwan University Hospital Cancer Registry records and pathological reports from 1977 to 1994 were reviewed. Empirical criteria were used to identify synchronous primary cancers.
RESULTS: A total of 322 patients had endometrial cancer and 421 patients had ovarian cancer in our Cancer Registry records. Eleven patients had simultaneous cancer involvement of both the endometrium and ovary. Six cases fulfilled the criteria of synchronous primary carcinomas of the endometrium and ovary. Of these, five were alive and free of disease for 35-144 months (median 94.2 months). The disease-free survival rates between patients with synchronous primary and metastatic cancers of different histologic types showed a statistically significant difference (P = 0.013). No statistical significance was noted for different histologic types (P > 0.5).
CONCLUSIONS: The empirical criteria used here were useful in identifying synchronous primary cancers of the endometrium and ovary. The favorable clinical outcome may relate to early detection of early-stage disease and low-grade malignancy with an indolent growth rate. Surgical management with or without adjuvant therapy has a satisfactory outcome in our experience.

Entities:  

Mesh:

Year:  1995        PMID: 8635635     DOI: 10.1016/0020-7292(95)02514-d

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  8 in total

1.  Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.

Authors:  Gulisa Turashvili; Natalia R Gómez-Hidalgo; Jessica Flynn; Mithat Gonen; Mario M Leitao; Robert A Soslow; Rajmohan Murali
Journal:  Gynecol Oncol       Date:  2018-11-06       Impact factor: 5.482

Review 2.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

3.  Endometrial Cancer: Comparison of Patients with Synchronous Primary Carcinoma of the Endometrium and Ovary vs. Endometrial Carcinoma with Ovarian Metastases.

Authors:  I Juhasz-Böss; T Fehm; S Becker; R Rothmund; B Krämer; A Staebler; D Wallwiener; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2012-08-16       Impact factor: 2.915

Review 4.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

5.  Premenopausal early-stage endometrial carcinoma patients with low CA-125 levels and low tumor grade may undergo ovary-saving surgery.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Woo Young Kim; Suk-Joon Chang; Hee-Jae Joo; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

6.  Systemic Sclerosis and Multiple Cancers of the Female Genital Tract: Prolonged Survival following Current Treatment Strategies.

Authors:  Georgios Androutsopoulos; Georgios Adonakis; Athanasios Tsamandas; Andreas Andonopoulos; Georgios Decavalas
Journal:  Case Rep Rheumatol       Date:  2012-01-04

7.  The Association between Primary Endometrioid Carcinoma of the Ovary and Synchronous Malignancy of the Endometrium.

Authors:  Catharina C van Niekerk; Johan Bulten; G Peter Vooijs; André L M Verbeek
Journal:  Obstet Gynecol Int       Date:  2009-12-15

8.  Synchronous double primary malignancies of the liver and kidney: A case report.

Authors:  Jun-Jun Sun; Tian-Bao Yang; Yan-Hui Yang; Wei-Feng Liu; Jun-Xin Song
Journal:  Oncol Lett       Date:  2016-02-08       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.